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The pharmacokinetic profiles of a traditional formulation of amphotericin B (Fungizone) and novel nano-
sphere and mixed micelle delivery systems developed for amphotericin B were compared and described. Six
groups of male Wistar rats received intravenous injections of the different formulations. Plasma and tissue
samples were obtained at 11 different times after dosing, with three animals used each time. The amphotericin
B concentrations in plasma and tissues were analyzed by high-performance liquid chromatography. The
plasma drug concentration-time profiles were best described by a two-compartment model. Models that
described the observed single or double peak disposition kinetics in kidney, liver, and spleen were also
developed. Parameter estimates from those models show that components of the formulation such as polox-
amer 188, which is present in all new formulations, seem to play an important role in the rate of drug uptake
by the tissues; in general, the levels of amphotericin B in tissues were increased after the administration of the
new formulations compared with those after the administration of Fungizone. The increment in the baseline
plasma creatinine level was used as an index of renal function. All formulations increased this baseline value,
but the novel formulations exhibited fewer renal effects than Fungizone did. However, a direct relationship
between drug exposure in the kidneys and development of renal damage could not be found.
Over the last 15 years there has been a dramatic increase in
fungal infections. This increased incidence can be attributed to
the lack of immunocompetence caused by chemotherapy, as
well as the spread of AIDS. Amphotericin B (AmB) is the most
effective and widely used antifungal agent for the treatment of
systemic fungal diseases. However, therapy with AmB is ham-
pered by a number of serious adverse effects such as fever,
chills, nausea, hypokalemia, and nephrotoxicity (23). In gen-
eral, all these side effects have been associated with undesir-
able increased and prolonged drug concentrations in tissues
such as the kidneys (16); therefore, a substantial effort has
been made toward the development of alternative formula-
tions for AmB administration, with the aim of improving the
therapeutic index of the drug by modifying the disposition in
the tissues of the body.
Several lipid-based formulations of AmB such as Ambisome
(liposomes), Amphocil (colloidal dispersion), and Abelcet (lip-
id complex) have appeared on the market over recent years (7,
15). The formulations have increased therapeutic indices with
respect to that of Fungizone (the traditional formulation for
AmB administration), but their higher economic costs are a
major limitation in therapeutics (9). Another alternative could
be the use of biodegradable polymeric carriers such as nano-
particles; these systems are thought to be more stable in bio-
logical fluids and during storage. Recently, different formula-
tions, (i) nanospheres formed by a polymeric core of poly
(e -caprolactone) coated with poloxamer 188 and AmB and (ii)
AmB-poloxamer 188 mixed micelles, have been developed in
our laboratory by Espuelas et al. (11). The doses that produce
50% mortality in mice (LD50s) for these two new AmB for-
mulations were higher than that of Fungizone. The LD50 was
calculated as the number of deaths that occurred when differ-
ent doses of the formulations were administered to mice by
intravenous injection (11).
To date, most of the new formulations are usually charac-
terized “in vivo” by means of the doses that elicit half of the
maximum efficacy (ED50s) (19) and LD50s (1). Estimates of
ED50 and LD50 include information on both the pharmacody-
namic and the pharmacokinetic properties of a drug, which
makes the interpretation of results a difficult task. In addition,
when pharmacokinetics is the aim of the study, in general,
values like the maximum concentration (Cmax), time at Cmax
(Tmax), area under the concentration-versus-time curve (AUC)
are reported. Although these values can be compared among
formulations to address differences in the formulations, they
cannot be used to describe and predict the time course of drug
concentrations in plasma and tissues, which in fact can deter-
mine the therapeutic and toxic effects. Therefore, the aim of
the current study was to characterize, by using pharmacoki-
netic models, the dispositions of new AmB formulations (11)
in the plasma, livers, spleens, and kidneys of rats. We also
include in the current study Fungizone as a reference formu-
lation. In addition, the effects of those AmB formulations on
renal function, measured as increasing levels of creatinine in
plasma, were also explored and quantified.
MATERIALS AND METHODS
Chemicals. AmB was kindly given by Bristol-Myers Squibb (Madrid, Spain),
and piroxicam (internal standard) was supplied by Boral Quı´mica (Barcelona,
Spain); desoxycholate-AmB (Fungizone) was purchased from Bristol-Myers
Squibb (Madrid, Spain). Poly( e -caprolactone; molecular weight, 42,500) and
poloxamer 188 (Pluronic F68) were supplied by Sigma (Madrid, Spain). A cre-
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atinine standard (3 mg/100 ml) was obtained from Sigma. All other chemicals
were of analytical grade and were purchased from standard commercial sources.
Preparation and characterization of AmB formulations. (i) Preparation of
AmB formulations for intravenous administration. (a) Fungizone. Fungizone
(deoxycholate-AmB) was reconstituted with sterile water and was further diluted
with a 5% glucose–water solution.
(b) AmB-Nsps. AmB-nanospheres (AmB-Nsps) with 125 mg of poloxamer 188
(AmB-Nsp [125]) were prepared by the solvent displacement method described
previously by Espuelas et al. (11). Briefly, in order to solubilize AmB (30 mg) and
poly(e -caprolactona) (125 mg), both were dissolved in 30 ml of a mixture of
organic solvents (methanol-acetone, 1:2 [vol/vol]) acidified with 0.1 N HCl to pH
3. This organic phase was heated at 50°C for 10 min and was thereafter poured
into 40 ml of distilled water by using poloxamer 188 (125 mg) as the surfactant
with moderate stirring with a magnetic stirrer. Finally, the preparation was
evaporated at 55 to 58°C under vacuum, and the final volume was adjusted to 10
ml. The formulations were neutralized with NaOH (0.1 N) to pH 5.5 before
administration.
AmB-Nsps with 12.5 mg of poloxamer 188 (AmB-Nsps [12.5]) were prepared
as described for AmB-Nsp [125], but with 12.5 mg of poloxamer 188.
(c) AmB-MMs. AmB-mixed micelles (AmB-MMs) with 125 mg of poloxamer
188 (AmB-MM [125]) were also prepared in the same way as AmB-Nsp [125] but
without poly( e -caprolactona).
AmB-MMs with 12.5 mg of poloxamer 188 (AmB-MM [12.5]) were prepared
as described for AmB-MM [125], but with 12.5 mg of poloxamer 188.
Fungizone was reconstituted just before drug injection as explained above;
AmB-Nsps and AmB-MMs were prepared on the day before the administration,
and the doses were adjusted just before injection.
(ii) Physicochemical characterization of the formulations. The physicochem-
ical characterization of the different novel formulations was performed on the
basis of two criteria, as published recently by Espuelas and coworkers (12, 13): (i)
particle size and (ii) UV-visible spectroscopy. Since AmB-MMs are colloidal
dispersions, for this particular case only UV-visible spectroscopy was used as a
criterion for characterization.
(a) Particle size. The mean particle size of the formulations was determined on
a Zetamaster Instrument (Zeta sizer 4; Malvern Instruments, Malvern, United
Kingdom). The measurements were performed after dilution (1:100) in distilled
water. The mean 6 standard deviation particle sizes of AmB-Nsp [125] and
AmB-Nsp [12.5] obtained were 280 6 30 and 350 6 70 nm, respectively, with
polydispersity indices of 0.1 for both formulations.
(b) UV-visible spectroscopy. The UV absorption of the formulation was de-
termined by diluting stock preparations (1 mg/ml) so that they contained a final
AmB concentration of 10 mg/ml. Absorption spectra were registered with a
Varian Cary 219 spectrophotometer.
In the absorption spectrum of Fungizone, a maximum of absorbance centered
at approximately 350 nm was observed. Otherwise, the spectrum corresponding
to AmB-Nsp [125] shows a new maximum of absorbance located at 375 nm. The
maximum of absorbance for AmB-Nsp [12.5] was found to be displaced with
respect to that for Fungizone. For AmB-MMs the results obtained were similar
to those observed for AmB-Nsps. These results suggest that the AmB aggrega-
tion state is modified by its association with nanospheres. The drug concentra-
tions in the dispersions were also calculated by measurement of the absorbance
at 405 nm after appropriate dilution in methanol.
Animals. With the approval of our Animal Care Committee, 231 male Wistar
rats (weight, 225 to 250 g) were used throughout the study. During the experi-
mental period the animals were housed individually in plastic cages at constant
temperature (25°C) and humidity (70%), with a 12-h light and 12-h dark cycle
(lights on from 8 a.m. to 8 p.m.). The rats were allowed free access to food and
water, but from 12 h before drug administration to 6 h after drug administration
food was withdrawn.
The animals were randomly divided into six groups (groups I to VI) of 33 rats
each. The animals were slightly anesthetized with ether, and the drug was ad-
ministered as a 5-min intravenous bolus injection through the vein tail. The
maximum injected volume was 1 ml (range, 0.7 to 1 ml). All drug administrations
were performed between 8 a.m. and 9 a.m. to minimize the potential influence of
circadian rhythms in the disposition of the drug.
Group I received a single dose of 1 mg of Fungizone per kg of body weight.
Groups II and III received single doses of 1 and 3 mg of AmB-MM [125] per kg,
respectively, and groups IV, V, and VI received single doses of 3 mg of
AmB-MM [12.5], AmB-Nsp [125], and AmB-Nsp [12.5] per kg, respectively. Just
before cervical dislocation, the animals were slightly anesthetized with ether, and
arterial blood (5 ml) was withdrawn from the abdominal aorta at the following
times after drug injection: 5, 10, 15, and 30 min and 1, 3, 6, 10, 24, 48, and 72 h
(three animals were used for each time point). At the time of killing, the kidneys,
liver, and spleen were removed, weighed, and frozen at 220°C until analysis;
blood samples were immediately centrifuged at 8,944 3 g for 10 min to obtain the
plasma. The plasma was also frozen until analysis of AmB and creatinine con-
centrations. Under these conditions the drug was found to be stable for at least
1 month.
HPLC assay. The levels of AmB in plasma and tissues were quantified by
high-performance liquid chromatography (HPLC). The method used for deter-
mination of the AmB concentrations in plasma and tissues was published re-
cently by Echevarrı´a et al. (10); briefly, an adequate amount of internal standard
(piroxicam) and 200 ml of acetonitrile were added to a 100-ml sample of plasma.
After vortex mixing (30 s), the sample was centrifuged at 8,944 3 g for 10 min.
The supernatant was evaporated to dryness in a vortex evaporator (60°C). The
residue was finally dissolved in 250 ml of the chromatographic eluent and filtered,
and 100 ml of this solution was injected into the HPLC system.
Liver, spleen, and kidney samples (0.5 g) were homogenized with an Ultra-
turrax-T25 dispersing apparatus (24,000 rpm, 3 min) with 2 ml of distilled water
containing the internal standard. A total of 300 ml of the homogenate was added
to 900 ml of methanol. The mixture was vortexed and centrifuged at 8,944 3 g for
10 min. The supernatant was filtered, and 100 ml was injected into the chromato-
graph.
The chromatography system consisted of a pump (Waters 600E), an autosam-
pler (Waters 700 Satellite WISP), an integrator (Waters 746), and a UV detector
(Waters 486) set at 405 nm. Separation was achieved with an Ultrabase C18
reverse-phase column (250 by 4.6 mm [inner diameter]; 5-mm particle size;
Scharlau, Barcelona, Spain), preceded by a guard column (45 by 4.6 mm [inner
diameter]) filled with pellicular C18 (5-mm particle size; Perkin-Elmer, Norwalk,
Conn.). The mobile phase was acetonitrile–acetic acid (10%)–water (41:43:16;
vol/vol) at a flow rate of 1 ml/min. Chromatography was carried out at room
temperature, and peak areas were measured for both AmB and the internal
standard.
The limit of quantitation (LOQ) for the quantification of AmB in plasma was
0.0066 mg/ml, with intraday variability, interday variability, and accuracy of 3.6,
6.8, and 4.5%, respectively.
For tissue samples, the LOQs were 0.2, 0.15, and 0.65 mg/g for the liver, spleen,
and kidney, respectively. The intraday variabilities, interday variabilities, and
accuracies were 4.2, 6.7, and 1.96%, respectively, for the liver, 6.8, 5.2, and 5.8%,
respectively, for the spleen, and 3.9, 3.8, and 4.4%, respectively, for the kidney.
Pharmacokinetic analysis. Pharmacokinetic analysis was carried out in two
steps. First, the kinetics in plasma were modeled, and during the second step,
drug profiles in the different tissues were described by using the predicted plasma
AmB concentration-versus-time profiles as the input function for the tissues.
(i) Step 1. Pharmacokinetics in plasma. The concentration-versus-time pro-
files for plasma were described by compartmental models, assuming first-order
disposition and elimination kinetics. During the simultaneous analysis of the data
obtained after the administration of doses of 1 and 3 mg of AmB-MM [125] per
kg, a model describing the elimination process as a saturable (concentration-
dependent) process was also evaluated.
The initial volume of distribution (V) and disposition and elimination rate
constants were estimated during the fit. Pharmacokinetic parameters such as
total plasma clearance (CL), apparent volume of distribution at steady-state
(VSS), mean residence time (MRT), AUC, disposition half-life (t1/2a), and elim-
ination half-life (t1/2b) were calculated from the estimated parameters by stan-
dard procedures (21).
(ii) Step 2. Pharmacokinetics in tissues. By exploration of the raw tissue AmB
concentration-versus-time data for all the six groups, a double concentration
peak was observed for liver and spleen. In order to describe this phenomenon
properly, a model describing the distribution of AmB from plasma to the tissues
by the use of two first-order distribution rate constants, as represented in Fig. 1A,
was fitted to the data. One of the rate constants (kk13) acts only at times longer
than the lag time (Tlag; a parameter also to be estimated by the model).
With respect to the kidneys, raw concentration-versus-time data revealed a
unique peak of drug concentration; in this case, a simpler model was fitted to the
data (Fig. 1B).
For each formulation and tissue, Cmax and Tmax were obtained by visual
inspection of the data. In order to be related to renal toxicity, the area under the
drug concentration in kidney-versus-time curve (AUCr) was calculated by the
trapezoidal rule.
(iii) Model selection. All the analyses were performed by the “naive pool data”
approach (14). This method consists of fitting all the data together as if they had
come from a single individual. In attempting to propose a model with the
maximum number of parameters in common between the six groups, the data for
all groups were fitted simultaneously. In the first stage, a reduced model was
fitted to the data; in this model the six groups share all the parameters. During
the following stage, the models fitted to the data have some but not all param-
eters in common for all groups, the last model fitted is the full model, which has
a completely different set of parameters for each group. All the analyses were
performed with the WinNonlin, version 1.5, computer program (Scientific Con-
sulting, Inc.).
In order to select the best pharmacokinetic model, a number of criteria,
including the Akaike information criterion (2), Schwartz criterion (22), and the
F test (6) were used. In the last of these, the calculated value of F may be
compared to the critical value derived from the distribution of F-Sne´de´cor table
in which the 5% level of significance is adopted.
In addition, the visual inspection of the residual plots and the calculated
coefficients of variation of the pharmacokinetic parameter estimates were also
used as a guide in selecting the best model. Coefficients of variation lower than
50% were considered acceptable.
Creatinine concentration determination. Creatinine concentrations in plasma
(CREA) were determined by the Taussky method (3), which is based on a color
reaction. Plasma samples for CREA determination were obtained at the same
time points and from the same animals used for AmB concentration determi-
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nation. In addition, baseline CREAs were measured in a small group of animals
(n 5 7). A total of 4.5 ml of picric acid (3.9 M) was added to 0.5 ml of plasma,
and the mixture was centrifuged at 880 3 g for 5 min, and then 1 ml of NaOH
(0.15 N) was added to 2.5 ml of the supernatant and the absorbances at 520 nm
were measured with a UV 1203 UV-Visible spectrophotometer (Shimadzu). For
each determination, 0.5 ml of a control solution and 0.5 ml of a blank solution
were prepared with 0.5 ml of a 3-mg/100 ml creatinine solution and 0.5 ml of
distilled water, respectively.
CREA was obtained by the following expression: CREA 5 (Absproblem/Abs-
control) z 3, where Absproblem and Abscontrol are the absorbances measured for
each plasma sample and for the control solution, respectively.
For each formulation all CREA-versus-time datum points were pooled, and
the area under the CREA-versus-time curve (AUCc) was calculated by the
trapezoidal rule and was normalized by dose; maximum CREA (Ccmax) and time
to Ccmax (Tcmax) were obtained by visual inspection of the data.
RESULTS
Pharmacokinetics of AmB in plasma. For all groups, a two-
compartment model adequately describes the kinetics of AmB
in plasma. Fig. 2A1, B1, and C1 show the adequacy of the
model describing the disposition of AmB in plasma for all
formulations tested during the study.
Although the same pharmacokinetic model was used for all
formulations, the values of the pharmacokinetic parameters
estimated differ among the formulations (P , 0.05). Table 1
lists the most representative pharmacokinetic parameters and
their coefficients of variation obtained from those estimated
during the fit. It can be observed that the parameters that
reflect distribution processes (t1/2a, V, VSS) vary the most
among the formulations. However, the calculated value of CL
is similar for all formulations.
The estimates of the pharmacokinetic parameters obtained
during the analysis of data for doses of 1 and 3 mg of AmB-
MM [125] per kg indicated the existence of differences in the
distribution process (P , 0.05) after the administration of the
two different doses, but the elimination of the drug was not
affected by the dose (P . 0.05).
Pharmacokinetics of AmB in tissue. (i) Liver. Figure 2A2,
B2, and C2 show the raw concentration-versus-time profiles
(depicted with symbols) in which the double peak can be ob-
served. Model predictions show the adequacy of the model in
describing the kinetics of AmB in liver. In addition, the phar-
macokinetic parameters were estimated with high precision
(coefficient of variation, ,25%) (Table 2). When estimating
kk13, the value of such an estimate was almost equal to the one
obtained for k13 for all the groups; for that reason we used a
simpler model in which kk13 was constrained to be equal to
k13. As for plasma, the model used was common for all
formulations, but the estimates of the parameters were not
(P , 0.05); k13 (kk13) ranged from 2.3 to 23.0 h
21, and k31
ranged from 0.5 to 5.9 h21. No differences in Tlag were found
(P . 0.05).
(ii) Spleen. The results obtained from the data on drug
disposition in the spleen were very similar to those obtained
from the data on drug disposition in the liver. The model
performed very well in predicting the concentration-versus-
time profiles (Fig. 2A3, B3, and C3). The pharmacokinetic
parameters (Table 2) varied significantly (P , 0.05) between
formulations, and all of them were estimated with enough
precision (coefficient of variation, ,45%). Tlag estimates were
not different among the new formulations (P . 0.05) but dif-
fered significantly from that for Fungizone (P , 0.05).
(iii) Kidney. Figure 2A4, B4, and C4 show the raw and
model prediction concentration data for some particular for-
mulations. Table 2 also lists the estimates of the parameters of
the disposition of AmB in the kidney. Parameter estimates also
show considerable differences between formulations (P , 0.05),
a pattern seen for the liver and spleen, as described above.
Creatinine concentration results. Table 3 lists the values of
the measurements used to evaluate renal function across for-
mulations. Ccmaxs tended, for all formulations, to be higher than
the baseline values and occurred within the first hour after
drug injection. On the basis of Ccmax values, Fungizone and
AmB-MM [125] could be considered the formulations with the
highest potential for nephrotoxicity because they had the
greatest effect on renal function.
DISCUSSION
At present AmB can be considered the first choice for the
treatment of disseminated mycoses, with nephrotoxicity being
the major limitation in therapeutics. In the current study the
disposition pharmacokinetics in plasma and tissue of novel and
traditional formulations of AmB after injection of an intrave-
nous bolus of AmB to rats were investigated.
FIG. 1. Scheme of the pharmacokinetic models proposed for the analysis of
AmB concentrations in liver and spleen (A) and in kidney (B). k10, first-order
elimination rate constant; k13 and k31, first-order distribution rate constants
between plasma and liver, spleen, or kidney; kk31, first-order plasma to tissue
(liver or spleen) distribution rate constant acting at times longer than Tlag; k12
and k21, first-order distribution rate constants between plasma and the peripheral
compartment.
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The study has focused mainly on modeling of the time
course of the drug in several tissues. The liver, spleen, and
kidney were chosen since the liver and spleen are the most
frequent organs where fungal infections appear, and the kid-
ney is the organ where AmB produces toxicity (5). We also
evaluated the effects of the different AmB formulations on
renal function in terms of the increment of creatinine levels in
plasma.
The studied formulations (nanospheres and mixed micelles)
have already been explored from an efficacy-versus-toxicity
perspective (11). In addition, their physicochemical character-
istics have previously been published by Espuelas et al. (12,
13). During the present study the procedure for developing
such formulations was similar to the one used by Espuelas et
al. (11), as were the results obtained during their character-
ization.
The pharmacokinetics of AmB in plasma for all formula-
tions were best described by a two-compartment model. The
pharmacokinetic parameters obtained for Fungizone were
similar to those obtained by other investigators when the ki-
FIG. 2. (A) Mean observed AmB concentrations (C) in plasma (A1), liver (A2), spleen (A3), and kidney (A4) for group I. (B) Mean observed AmB concentrations
in plasma (B1), liver (B2), spleen (B3), and kidney (B4) for groups III (F) and IV (). (C) mean observed AmB concentrations in plasma (C1), liver (C2), spleen (C3),
and kidney (C4) for groups V (F) and VI (). Solid lines, model predictions.
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netics of this formulation were compared with those of
Abelcet after administration of single or repeated doses in
rats (4, 20).
The disposition of the AmB-MM [125] formulation at two
different doses (1 and 3 mg/kg) was evaluated in plasma; phar-
macokinetic distribution parameters changed significantly with
dose, suggesting that for a particular formulation distribution
mechanisms are dose dependent at this range of doses. After
the administration of three different doses (0.28, 0.45, and 0.84
mg/kg, respectively) of Fungizone by intravenous infusion to
rats, Chow et al. (8) did not observe the dose dependence, but
recently, several investigators observed this phenomenon after
the administration of liposomal AmB to rabbits (17) and neu-
tropenic patients (25).
On the basis of our results it seems that the different com-
ponents of the formulations such as poloxamer 188 and poly(e -
caprolactona) do not modify the elimination of the drug, as no
differences in CL were observed between formulations. On the
other hand, the distribution process reflected by t1/2a, V, and
VSS seems to differ among formulations to a high degree, which
could be considered a priori an initial goal in the development
of new formulations. In general, the Cmaxs in the tissues stud-
ied were higher for all new formulations than for the reference
formulation (Table 2).
Exploring the raw concentration-versus-time profiles, a dou-
ble peak of concentration was found in the liver and spleen for
all formulations. Our analytical technique could not distinguish
between free or complexed AmB, in fact, the total AmB con-
centration (the AmB concentration in plasma plus the AmB
bound to the component of the formulation) in plasma and
tissues was determined. The physiological explanation for this
phenomenon could be connected to the fact that the entrance
of free AmB and AmB-poloxamer complex into the liver and
spleen takes place in different ways, depending on whether
AmB is free. Our hypothesis is that, first, the AmB-poloxamer
188 complex gains access to the tissues (first concentration
peak). AmB returns to the plasma once the complex has been
degraded into the tissue, and then there is a redistribution of
free AmB into the tissue (second peak). This is the first time
that such a behavior has been observed and was not observed
previously probably owing to the need for an intensive sam-
pling over a short period of time. Tissue AmB concentrations
TABLE 1. Estimates of values for pharmacokinetic parameters in plasma and their coefficients of variation
after an intravenous bolus injection of AmB
Pharmacokinetic
parameter
Formulation (dose)
Fungizone
(1 mg/kg)
AmB-Nsp [125]
(3 mg/kg)
AmB-Nsp [12.5]
(3 mg/kg)
AmB-MM [125]
(1 mg/kg)
AmB-MM [125]
(3 mg/kg)
AmB-MM [12.5]
(3 mg/kg)
t1/2a (h) 0.125 (40)
a 0.95 (21) 0.65 (28) 0.18 (32) 0.10 (24) 0.09 (26)
t1/2b (h) 19.6 (5) 23.5 (8) 18.2 (10) 23.1 (21) 23.1 (12) 21.8 (14)
AUC (mg z h/ml) 37.4 (4) 100 (3) 141 (8) 47.4 (14) 102 (10) 96.8 (8)
CL (ml/h/kg) 27 (4) 30 (3) 21 (8) 21 (14) 29 (10) 30 (8)
V (ml/kg) 253.6 (24) 253.6 (5) 108.4 (17) 103 (24) 121 (63) 121.2 (16)
VSS (ml/kg) 744 (6) 892 (6) 472 (11) 672 (13) 949 (13) 812 (13)
MRT (h) 27.9 (5) 27.2 (6) 23.4 (11) 31.9 (21) 32.4 (14) 26.9 (14)
a Values in parentheses are coefficients of variation (in percent).
TABLE 2. Estimates of values for pharmacokinetic parameters and their coefficients of variation and observed Cmax and Tmax values
for different tissues after an intravenous bolus injection of AmB
Tissue and
pharmacokinetic
parameter
Formulation (dose)
Fungizone
(1 mg/kg)
AmB-Nsp [125]
(3 mg/kg)
AmB-Nsp [12.5]
(3 mg/kg)
AmB-MM [125]
(1 mg/kg)
AmB-MM [125]
(3 mg/kg)
AmB-MM [12.5]
(3 mg/kg)
Liver
k13 5 kk13 (h
21) 4.4 (15)a 5.5 (18) 2.45 (15) 9.7 (9) 23.0 (10) 2.3 (17)
k31 (h
21) 4.13 (20) 5.9 (22) 1.13 (22) 2.8 (14) 4.2 (17) 0.5 (24)
Tlag (h) 3 3 3 3 3 3
Cmax (mg/g) 4.23 6 1.20
b 9.23 6 1.39 30.3 6 2.29 12.5 6 2.82 49.3 6 6.33 42.5 6 4.34
Tmax (h) 0.083 0.25 0.5 0.25 0.167 0.5
Spleen
k13 5 kk13 (h
21) 6.6 (17) 13.7 (18) 6.9 (9) 28 (37) 15.3 (17) 4.17 (9)
k31 (h
21) 5.23 (20) 5.58 (21) 2.78 (13) 12.2 (14) 3.7 (20) 0.99 (15)
Tlag (h) 6 3 3 10 10 10
Cmax (mg/g) 4.30 6 0.18 31.3 6 1.52 50.6 6 13.4 19.9 6 4.71 53.9 6 7.29 37.7 6 3.90
Tmax (h) 0.25 0.5 0.167 0.083 0.25 1
Kidney
k13 (h
21) 4.61 (13) 1.99 (15) 0.6 (13) 1.95 (15) 1.5 (16) 0.3 (17)
k31 (h
21) 4.42 (17) 1.35 (22) 0.3 (23) 0.76 (22) 0.42 (20) 0.08 (27)
AUC1 (mg z h/g) 20.58 (11) 96.32 (21) 163.9 (8) 162.6 (11) 207.8 (13) 206.3 (6)
Cmax (mg/g) 2.4 6 0.34 9.2 6 0.07 9.11 6 0.95 5.71 6 0.59 9.25 6 0.29 6.5 6 0.50
Tmax (h) 0.25 0.5 1 3 6 0.167
a Values in parentheses are coefficients of variation (in percent).
b Mean 6 standard deviation.
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were measured six times in the first 3 h of the study. The
parameter called Tlag may represent both the degradation of
the poloxamer 188 complex in tissue and the return of free
AmB to the plasma compartment. In principle, one can think
that the particular size or liposolubility of formulations could
influence Tlag. In fact, there were differences in this parameter
for the spleen, depending on the type of formulation; Tlags
were estimated to be 3, 6, and 10 h for AmB-Nsps, Fungizone,
and AmB-MMs, respectively. However, no differences were
seen between the Tlag values for the new formulations for the
liver.
The estimated values of k13 and kk13 were similar, probably
indicating that the distribution of complexed AmB and free
AmB is a perfusion rather than a permeation limitation pro-
cess. By exploring the rate constants for the drug entering the
liver and spleen and comparing these constants for the various
formulations, it was found that components of the polymeric
formulations such as poloxamer 188 are important determi-
nants in the rate of drug uptake in those organs. As shown in
Table 4, an increase in the polymer concentration can result in
higher values for k13 in AmB-Nsps and AmB-MMs for the liver
and spleen. This finding is in agreement with those of other
investigators who have presented results that suggest that, in
general, with the exception of poloxamer 188, surfactants can
decrease the rate of penetration into tissue (18).
The physicochemical characteristics of the novel formula-
tions such as the size, the liposolubility, and the proportion of
the different components of the formulations may play an
important role in the pharmacokinetics of the formulation.
When we tried to correlate these characteristics with the phar-
macokinetic estimates obtained, the only relationship that
we could establish was the one discussed above regarding
the impact of poloxamer 188 on the rate constants for in-
put into the liver and spleen. On the basis of these results,
if quick, high levels of drug in those tissues are desired, the
use of more poloxamer 188 in the formulation is recom-
mended.
Particularly for AmB-Nsps, the drug is adsorbed into the
particle surface. When these nanospheres are prepared with
poloxamer 188, this polymer is also adsorbed into the surface
and AmB forms mixed micelles with the nonadsorbed polymer
(80%). The mixed system is formed by the AmB adsorbed into
the particle and mixed micelles of AmB-poloxamer 188 (12,
13). The size of the AmB-poloxamer 188 complex is recognized
by the macrophages present in the liver and spleen, with this
phenomenon being responsible for the differences in pharma-
cokinetics seen between formulations.
For the case of the kidney, no double peak was found and all
formulations showed similar Cmax values (when normalized by
dose), supporting the hypothesis that only free AmB is able to
access the kidney. The AUCr value was lower for Fungizone
than for the rest of the formulations, but surprisingly, renal
toxicity (measured as increasing levels of creatinine in plasma)
was found to be higher for Fungizone. Among the new formu-
lations, AmB-MM [12.5] exhibited the greatest effect on the
kidney and could be considered the most nephrotoxic. A sim-
ilar result had previously been reported by Espuelas et al. (11),
as determined by using LD50s for mice. Increasing levels of
creatinine in plasma have also been used by other investiga-
tors, resulting in a good index that can be used to explore the
effect of AmB on renal function (17, 26). The possibility exists
that the polymeric components of the formulation, poloxamer
188 and poly(e caprolactone), may produce renal dysfuction.
However, they are nontoxic polymers, and no increases in
creatinine levels were observed. In addition, the LD50 of polox-
amer 188 when administered to rats is 7 g/kg, and 0.5 mg/kg
was the dose administered in this study (24).
Our results indicate that there is no direct relationship be-
tween drug disposition in the kidney (reflected as Tmax, Cmax,
or AUCr) and a renal effect. Such a relationship suggests
instead a need for a complex analysis like pharmacodynamic
modeling to relate drug exposure to the effect on renal func-
tion.
To summarize the results of the current study, the disposi-
tions of new formulations of AmB in plasma, liver, spleen, and
kidney have been characterized with pharmacokinetic models.
The profiles for plasma were best characterized by a two-
compartment model, with distribution being the process that
varied the most between formulations. To describe the dispo-
sition of AmB in liver and spleen, a model with two first-order
rate constants that account for the transfer from plasma to the
tissues was fitted to the data. Our results suggest that polox-
amer 188 plays an important role in the disposition of AmB in
tissue. The effects of the formulations on renal function were
also evaluated, but no relationship between drug disposition in
kidney and increasing levels of creatinine in plasma was found.
All new formulations tested show fewer renal effects than the
reference formulation Fungizone.
TABLE 3. Renal toxicity-related measurements obtained from creatinine levels in plasma
Parameter
Formulation (dose)
Fungizone
(1 mg/kg)
AmB-Nsp [125]
(3 mg/kg)
AmB-Nsp [12.5]
(3 mg/kg)
AmB-MM [125]
(1 mg/kg)
AmB-MM [125]
(3 mg/kg)
AmB-MM [12.5]
(3 mg/kg)
AUCc (mg z h/100 ml) 134 26.3 47 118 48 178
Ccmax (mg/100 ml) 5.0 6 2.6
a 1.8 6 0.4 1.7 6 0.6 2.1 6 0.7 1.9 6 0.4 7.7 6 2.6
Tcmax (h) 0.25 0.5 0.25 0.167 0.5 0.25
a Mean 6 standard deviation.
TABLE 4. Comparison between concentration of poloxamer 188
used for each of the polymeric formulations on
the basis of k13 (kk13) and k31 estimates
Tissue and
pharmacokinetic
parameter
Formulation (dose)
AmB-Nsp
[125]
(3 mg/kg)
AmB-Nsp
[12.5]
(3 mg/kg)
AmB-MM
[125]
(3 mg/kg)
AmB-MM
[12.5]
(3 mg/kg)
Liver
k13 5 kk13 (h
21) 5.5 (18)a 2.45 (15) 23.0 (10) 2.3 (17)
k31 (h
21) 5.9 (22) 1.13 (22) 4.2 (17) 0.5 (24)
Spleen
k13 5 kk13 (h
21) 13.7 (18) 6.9 (9) 15.3 (17) 4.17 (9)
k31 (h
21) 5.58 (21) 2.78 (13) 3.7 (20) 0.99 (15)
a Values in parentheses are coefficients of variation (in percent).
VOL. 44, 2000 DISPOSITION AND EFFECT OF AmB ON RENAL FUNCTION 903
ACKNOWLEDGMENT
This work was partially supported by Proyectos de Investigacio´n
Universidad de Navarra (grant PIUNA-96 240501), Pamplona, Na-
varra, Spain.
REFERENCES
1. Adler-Moore, J. P., G. Fuji, and M. A. Lee. 1993. In vitro and in vivo inter-
actions of Ambisome with pathogenic fungi. J. Liposome Res. 3:151–156.
2. Akaike, H. 1974. A new look at the statistical model identification. IEEE
Trans. Automat. Control 19:716–723.
3. Bartels, H., M. Bo¨hmer, and C. Heierli. 1972. Serum Kreatinibestimmung
ohne Enteiweissen. Clin. Chim. Acta 37:193–197.
4. Bhamra, R., A. Sa’ad, L. E. Bolcsak, A. S. Janoff, and C. E. Swenson. 1997.
Behaviour of amphotericin B lipid complex in plasma in vitro and in the
circulation of rats. Antimicrob. Agents Chemother. 41:886–892.
5. Boswell, G. W., I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. 1998.
Toxicological profile and pharmacokinetics of a unilamellar liposomal vesi-
cle formulation of amphotericin B in rats. Antimicrob. Agents Chemother.
42:263–268.
6. Boxenbaum, H. G., S. Riegelman, and R. M. Elashoff. 1974. Statistical
estimations in pharmacokinetics. J. Pharmacokinet. Biopharm. 2:123–148.
7. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of
amphotericin B. Clin. Microbiol. Rev. 9:512–531.
8. Chow, H. H., Y. Wu, and M. Mayersohn. 1995. Pharmacokinetics of ampho-
tericin B in rats as a function of dose following constant-rate intravenous
infusion. Biopharm. Drug Dispos. 16:461–473.
9. Cooke, J. 1994. Pharmacoeconomics of antifungal therapy. Bone Marrow
Transplant. 14(Suppl. 5):S18–S20.
10. Echevarrı´a, I., C. Barturen, M. J. Renedo, and M. C. Dios-Vie´itez. 1998.
High-performance liquid chromatographic determination of amphotericin B
in plasma and tissue. Application to pharmacokinetic and tissue distribution
studies in rats. J. Chromatogr. A 819:171–176.
11. Espuelas, M. S., P. Legrand, J. M. Irache, C. Gamazo, A. M. Orecchioni,
J.-P. Devissaguet, and P. Ygartua. 1997. Poly( e -caprolactone) nanospheres
as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158:
19–27.
12. Espuelas, M. S., P. Legrand, M. Che´ron, G. Barratt, F. Puisieux, J.-P.
Devissaguet, and J. M. Irache. 1998. Interaction of amphotericin B with
polymeric colloids. 1. A spectroscopic study. Colloid. Surf. B Biointerf. 11:
141–151.
13. Espuelas, M. S., P. Legrand, M. Che´ron, G. Barratt, F. Puisieux, M. J.
Renedo, J.-P. Devissaguet, and J. M. Irache. 1998. Interaction of amphoter-
icin B with polymeric colloids. 2. Effect of poloxamer on the adsorption of
amphotericin B onto poly( e caprolactone) nanospheres. Colloid. Surf. B
Biointerf. 11:203–212.
14. Garrido, M. J., M. Valle, R. Calvo, and I. F. Troco´niz. 1999. Altered plasma
and brain disposition and pharmacodynamics of methadone in abstinent rats.
J. Pharmacol. Exp. Ther. 288:179–187.
15. Hillery, A. M. 1997. Supramolecular lipidic drug delivery systems: from
laboratory to clinic. A review of the recently introduced commercial liposo-
mal and lipid-based formulations of amphotericin B. Adv. Drug Deliv. Rev.
24:345–363.
16. Kreft, B., C. De Wit, R. Marre, and K. Sack. 1991. Experimental studies on
the nephrotoxicity of amphotericin B in rats. J. Antimicrob. Chemother. 28:
271–281.
17. Lee, J. W., M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A.
Pizzo, and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar
liposomal formulation of amphotericin B (Ambisome) in rabbits. Antimi-
crob. Agents Chemother. 38:713–718.
18. Moghimi, S. M. 1995. Mechanisms regulating body distribution of nano-
spheres conditioned with pluronic and tetronic block co-polymers. Adv.
Drug Deliv. Rev. 16:183–193.
19. Mu¨llen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the
efficacies of various formulations of amphotericin B against murine viceral
leishmaniasis. Antimicrob. Agents Chemother. 41:2089–2092.
20. Olsen, S. J., M. R. Swerdel, B. Blue, J. M. Clark, and D. P. Bonner. 1991.
Tissue distribution of amphotericin B lipid complex in laboratory animals.
J. Pharm. Pharmacol. 43:831–835.
21. Rowland, M., and T. N. Tozer. 1995. Clinical pharmacokinetics. Concepts
and applications, 3rd ed. The William & Wilkins Co., Media, Pa.
22. Schwarz, G. 1978. Estimating the dimension of a model. Ann. Stat. 6:461–
468.
23. Tasset, C., V. Preat, A. Bernard, and M. Roland. 1992. Comparison of
nephrotoxicities of different polyoxyethyleneglycol formulations of ampho-
tericin B in rats. Antimicrob. Agents Chemother. 36:1525–1531.
24. Wade, A., and P. J. Weller. 1994. Handbook of pharmaceutical excipients,
p. 352. American Pharmaceutical Association, Washington, D.C.
25. Walsh, T. J., V. Yeldandi, M. Mcevoy, C. Gonzalez, S. Chanock, A. Freifeld,
N. I. Seibel, P. O. Withcomb, P. Jarosinsky, G. Boswell, I. Bekersky, A. Alak,
D. Buell, J. Barret, and W. Wilson. 1998. Safety, tolerance, and pharmaco-
kinetics of a small unilamellar formulation of amphotericin B (Ambisome) in
neutropenic patients. Antimicrob. Agents Chemother. 42:2391–2398.
26. Wasan, K. M., A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J.
Wen-Lin Chou, and P. H. Pritchard. 1998. Pharmacokinetics, distribution in
serum lipoproteins and tissues, and renal toxicities of amphotericin B and
amphotericin B lipid complex in a hypercholesterolemic rabbit model: sin-
gle-dose studies. Antimicrob. Agents Chemother. 42:3146–3152.
904 ECHEVARRI´A ET AL. ANTIMICROB. AGENTS CHEMOTHER.
